Navigation Links
Takeda Announces New U.S. Leadership
Date:3/19/2008

Proposed appointments effective at conclusion of TAP transaction

DEERFIELD, Ill., March 19 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced proposed new leadership for Takeda America Holdings, Inc. (TAH), Takeda Pharmaceuticals North America, Inc. (TPNA) and Takeda Global Research & Development Center, Inc. (TGRD) following an earlier announcement related to Takeda's plans to conclude its joint venture in the United States, TAP Pharmaceutical Products Inc. (TAP).

Effective at the close of the TAP transaction, Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. will report to Takeda America Holdings, Inc. Alan MacKenzie, the current president of TAP and a former president of Takeda Pharmaceuticals North America, Inc. has been named executive vice president of Takeda America Holdings.

MacKenzie will also serve as CEO of Takeda Pharmaceuticals North America, Inc. in addition to his role as executive vice president of Takeda America Holdings.

Mark Booth, current president of Takeda Pharmaceuticals North America, Inc., will continue to lead the company until the TAP transaction is closed and has agreed to continue on with the company for some period thereafter to support integration activities.

Reporting to MacKenzie as president of Takeda Global Research & Development Center, Inc. will be Nancy Joseph-Ridge, M.D., currently TAP's vice president of research and development. Dr. Joseph-Ridge will also assume her position effective the close of the TAP transaction.

"I have great confidence in Takeda's proposed new leadership for the United States, an important market for Takeda's global growth plans," said Yasuchika Hasegawa, president, Takeda Pharmaceutical Company Limited. "Alan MacKenzie not only helped launch both TPNA and its first product, Actos, he has been instrumental in helping create success at Takeda companies for more than 22 years. Dr. Nan
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Takeda submits new drug application for alogliptin (syr-322) in the US
2. Chemizon Announces Research Collaboration Expansion With Takeda
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
5. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
6. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
7. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
8. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
9. PRA International Announces New Office Opening in Mumbai
10. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
11. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...wed cell growth, study says , , WEDNESDA... for many years to treat irregular heart rhythms a...ent, researchers report. , Cancer cells need to...these cells are oxygen-deprived and need to switch...ducible factor (HIF-1), which help cells survive i...
(Date:1/7/2009)...ire/ -- A medical revolution emerges when,technol...makes this connection,with its new Smart OR(TM) -...e-of-the-art treatment for neurosurgery, spine and...scom.com/cgi-bin/prnh/20081016/CLTH057 ) , ...echnology, the Smart OR,helps neurosurgeons perfo...
(Date:1/7/2009)...lobal team , , DENVER, Jan. 7 C...acturer of technical ceramics in North America, an...e company as Sales Manager for Orthopaedic and Med...iness development and technical support functions ...n addition to supporting new product development o...
(Date:1/7/2009)...eptible, study suggests , , WEDNESDAY, J...more than two hours of "screen time" a day watchin...ikely to be physically fit, a new Australian study...the same study were more likely to be able to "sit...tdoctoral fellow at the New South Wales Centre for...
Breaking Medicine News(10 mins):Health News:Heart Drug May Be a Cancer Fighter 2Health News:A New, 'Smart' Approach to Brain and Spine Surgery 2Health News:A New, 'Smart' Approach to Brain and Spine Surgery 3Health News:Dr. Steven Hughes Joins Medical Ceramics Provider: C5 Medical Werks 2Health News:More 'Screen Time' Linked to Poor Fitness in Girls 2
...A is about to embark upon a health revolution that...nd hope for paraplegics to walk again.// This is ...e nominated seven medical advances which they cons... technology stem cell science, and bionic innovati...
...al abnormalities were found in a particular brain ...according to a study conducted// at the Laboratory...for Biological Studies. Williams syndrome is a ra...ren love music and, will therefore spend hours lis...
...le of the National Breast Feeding week included an...ttitudinal challenges// that pose a major hurdle t... western countries, Ireland has one of the lowest ...acclaimed breastfeeding specialist, Dr Jack Newman...
...researchers found that curcumin — a chemical found...m clear the brain //of amyloid beta, which form th...in the Oct. 9 issue of the Journal of Alzheimer’s ... may lead to a new approach in treating Alzheimer’...
Other Medicine News:Health News:Age of Medical Miracles has come upon us 2Health News:Chemical in Curry May Help Immune System Clear Plaques Found in Alzheimer's 2
(Date:1/3/2009)... , , , , ROSEMONT, Ill., Jan. 2 ...ing (MRI) is a growing technology providing an inc...he evaluation of back pain according to an article...merican Academy of Orthopaedic Surgeons ( http://w...xt several years, additional technical development...
(Date:12/27/2008)...rigitte Boisselier breaks 5-year silence, offers t...o go public , , LAS VEGAS, Dec. 27 /PRNewswire-...h of Baby Eve, the first cloned child, Dr. Brigitt...lonaid project, said Eve and other babies cloned b...and with no one invading their families, privacy. ...
(Date:12/17/2008)...RANCISCO, Dec. 17 Mediva... it has completed patient enrollment in a,Phase 1...novel androgen,receptor antagonist, in castration...will seek approval from the U.S. Food and Drug Adm...trials next year. , The open-label, U.S. Ph...
(Date:12/16/2008)...rch Uncovers New Link Between Inflammation & A... 16 The Roskamp Institute today an...link between inflammation and Alzheimer,s disease ...ing novel therapeutics for intervention in this di...ham Bakshi, Ph.D., is detailed in the American Ch...
Breaking Medicine Technology:MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3'We're Ready to Prove It!' 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 2Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 3DSM Biologics and Crucell Announce Commercial PER C6 28R 29 Licensing Agreement with Gedeon Richter 9344 1DSM Biologics and Crucell Announce Commercial PER C6 28R 29 Licensing Agreement with Gedeon Richter 9344 2DSM Biologics and Crucell Announce Commercial PER C6 28R 29 Licensing Agreement with Gedeon Richter 9344 3DSM Biologics and Crucell Announce Commercial PER C6 28R 29 Licensing Agreement with Gedeon Richter 9344 4Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr 30575 1Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr 30575 2Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr 30575 3Medicsight Announces New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008 30572 1Medicsight Announces New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008 30572 2Medicsight Announces New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008 30572 3t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application 9342 1t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application 9342 2
...ISO VIEJO, Calif.--(BUSINESS WIRE)--Apr 18, 2007 -...ced positive top-line,results from the company,s P...onal drug Zenvia(TM) (dextromethorphan,hydrobromid...nd,sigma-1 agonist, in diabetic neuropathic pain.,...e daily diary,entries for the Pain Rating Scale as...
...Immunization with a Bavituximab Equivalent and Irr...o 57% From 0% in Controls in a,Preclinical Model o...April 18, 2007,/PRNewswire-FirstCall/ -- Peregrine...aceutical company developing targeted,monoclonal a...s C,virus (HCV) infection, today announced preclin...
Other Medicine Technology:Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 2Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 3Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 4Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 5Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain 6Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 2Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 3Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 4Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 5Data Presented at AACR Meeting Show Peregrine's Bavituximab,Equivalent Can Generate Curative Immune Responses as Part of a,Vaccine-Like Regimen in Preclinical Models of Aggressive Brain,Cancer 6
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity.
It is lightweight and portable headlight option for office exam room. It offers complete comfort and portability.
Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear.
Coaxial fiberoptic headlight has fixed spot size of 120mm. It weighs only 4.5 ounces.
Medicine Products: